Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control

Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn and Alfred Morgenstern
Journal of Nuclear Medicine May 2018, 59 (5) 795-802; DOI: https://doi.org/10.2967/jnumed.117.203539
Clemens Kratochwil
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bruchertseifer
2Directorate for Nuclear Safety and Security, Joint Research Centre, European Commission, Karlsruhe, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendrik Rathke
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Hohenfellner
3Department of Urology, University Hospital Heidelberg, Heidelberg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik L. Giesel
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
4Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Morgenstern
2Directorate for Nuclear Safety and Security, Joint Research Centre, European Commission, Karlsruhe, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 59 no. 5 795-802
DOI 
https://doi.org/10.2967/jnumed.117.203539
PubMed 
29326358

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication October 16, 2017
  • Accepted for publication December 7, 2017
  • Published online May 1, 2018.

Article Versions

  • previous version (January 11, 2018 - 12:27).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Clemens Kratochwil1,
  2. Frank Bruchertseifer2,
  3. Hendrik Rathke1,
  4. Markus Hohenfellner3,
  5. Frederik L. Giesel1,
  6. Uwe Haberkorn*,1,4 and
  7. Alfred Morgenstern*,2
  1. 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  2. 2Directorate for Nuclear Safety and Security, Joint Research Centre, European Commission, Karlsruhe, Germany
  3. 3Department of Urology, University Hospital Heidelberg, Heidelberg, Germany; and
  4. 4Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
  1. For correspondence or reprints contact: Clemens Kratochwil, Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany. E-mail: clemens.kratochwil{at}med.uni-heidelberg.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 210 Citations
  • 239 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
    Thomas I. Kostelnik, Chris Orvig
    Chemical Reviews 2019 119 2
  • 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
    Mike Sathekge, Frank Bruchertseifer, Otto Knoesen, Florette Reyneke, Ismaheel Lawal, Thabo Lengana, Cindy Davis, Johncy Mahapane, Ceceila Corbett, Mariza Vorster, Alfred Morgenstern
    European Journal of Nuclear Medicine and Molecular Imaging 2019 46 1
  • EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
    Clemens Kratochwil, Wolfgang Peter Fendler, Matthias Eiber, Richard Baum, Murat Fani Bozkurt, Johannes Czernin, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levant Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M. Mottaghy, Wim Oyen, Kambiz Rahbar, Heiko Schöder, Irene Virgolini, Hans-Jürgen Wester, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Herrmann
    European Journal of Nuclear Medicine and Molecular Imaging 2019 46 12
  • Recent Advances in Prostate Cancer Treatment and Drug Discovery
    Ekaterina Nevedomskaya, Simon Baumgart, Bernard Haendler
    International Journal of Molecular Sciences 2018 19 5
  • Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
    Thomas Langbein, Wolfgang A. Weber, Matthias Eiber
    Journal of Nuclear Medicine 2019 60 Supplement 2
  • Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines
    E. Johanna L. Stéen, Patricia E. Edem, Kamilla Nørregaard, Jesper T. Jørgensen, Vladimir Shalgunov, Andreas Kjaer, Matthias M. Herth
    Biomaterials 2018 179
  • Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
    Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel O. Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Florette Reyneke, Alex Maes, Clemens Kratochwil, Thabo Lengana, Frederik L. Giesel, Christophe Van de Wiele, Alfred Morgenstern
    Journal of Nuclear Medicine 2020 61 1
  • Radiotheranostics: a roadmap for future development
    Ken Herrmann, Markus Schwaiger, Jason S Lewis, Stephen B Solomon, Barbara J McNeil, Michael Baumann, Sanjiv S Gambhir, Hedvig Hricak, Ralph Weissleder
    The Lancet Oncology 2020 21 3
  • A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
    Denise S. O’Keefe, Dean J. Bacich, Steve S. Huang, Warren D.W. Heston
    Journal of Nuclear Medicine 2018 59 7
  • 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Fadi Khreish, Niklas Ebert, Martin Ries, Stephan Maus, Florian Rosar, Hendrik Bohnenberger, Tobias Stemler, Matthias Saar, Mark Bartholomä, Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging 2020 47 3

Article usage

Article usage: January 2018 to December 2022

AbstractFullPdf
Jan 20187200182
Feb 2018309087
Mar 20182510103
Apr 20182640108
May 2018159379208
Jun 20184203970
Jul 20182233644
Aug 20181594449
Sep 201835346135
Oct 201831741108
Nov 201830897140
Dec 201827077122
Jan 201926778131
Feb 201925954127
Mar 201924070150
Apr 201920361118
May 201929493113
Jun 201916471101
Jul 20191485476
Aug 20191515193
Sep 20191615195
Oct 201913675100
Nov 20191377397
Dec 20191426471
Jan 20202267092
Feb 20202576786
Mar 2020124592105
Apr 202054675105
May 20201096567
Jun 2020885676
Jul 20201693145
Aug 2020756986
Sep 2020724941
Oct 2020764358
Nov 2020725570
Dec 2020616675
Jan 202148131111
Feb 2021319570
Mar 202154146111
Apr 20212713666
May 20213911778
Jun 20212914386
Jul 20214210082
Aug 20212910390
Sep 202149108113
Oct 20214411396
Nov 202138131105
Dec 20212513250
Jan 20223011148
Feb 2022369972
Mar 20223611071
Apr 2022349884
May 20222610266
Jun 20223710760
Jul 2022297961
Aug 2022389787
Sep 20222811358
Oct 20222910956
Nov 20223412180
Dec 20222511451
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (5)
Journal of Nuclear Medicine
Vol. 59, Issue 5
May 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn, Alfred Morgenstern
Journal of Nuclear Medicine May 2018, 59 (5) 795-802; DOI: 10.2967/jnumed.117.203539

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L. Giesel, Uwe Haberkorn, Alfred Morgenstern
Journal of Nuclear Medicine May 2018, 59 (5) 795-802; DOI: 10.2967/jnumed.117.203539
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
  • Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
  • Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
  • The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
  • First Clinical Results for PSMA-Targeted {alpha}-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
  • The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
  • Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
  • JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
  • Patients Resistant Against PSMA-Targeting {alpha}-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes
  • Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy
  • Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
  • {alpha}-Particle-Emitter Radiopharmaceutical Therapy: Resistance Is Futile
  • Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice
  • Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
  • Melanocortin 1 Receptor-Targeted {alpha}-Particle Therapy for Metastatic Uveal Melanoma
  • Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
  • Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
  • Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
  • Google Scholar

More in this TOC Section

Theranostics

  • Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
  • The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy
  • Fibroblast activation protein positron emission tomography and histopathology in a single-center database of 324 patients and 21 tumor entities
Show more Theranostics

Clinical

  • Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
  • The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy
  • Fibroblast activation protein positron emission tomography and histopathology in a single-center database of 324 patients and 21 tumor entities
Show more Clinical

Similar Articles

Keywords

  • PSMA
  • Ac-225
  • 225Ac
  • targeting therapy
  • Prostate cancer
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire